Abstract submitters may participate in the application process for the following awards:
One abstract of each digital oral presentation session has been nominated for this award by the chairs of the respective sessions.
The winners of the Top 10 DOP awards are:
DOP07: Chronic abdominal pain in IBD patients in remission: Real-world data on contributing factors - Ashkan Rezazadeh Ardabili, Maastricht, The Netherlands
DOP14: Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study - Richard James Michael Ingram, Alberta, Canada
DOP22: Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort study - Mohamed Attauabi, Hvidovre, Denmark
DOP33: Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence model - Anthony Buisson, Clermont-Ferrand, France
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative Colitis - Timothy Raine, Cambridge, United Kingdom
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBD - Joachim Hanna, Cambridge, United Kingdom
DOP59: Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML) - David Rubin, Chicago, United States
DOP69: Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN - Anat Guz Mark, Petah Tikva, Israel
DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD) - María José García, Santander, Spain
DOP89: Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease - Zhigang Wang, Leuven, Belgium
The Clinical Research Committee of ECCO (ClinCom) wants to stimulate the development of high-quality Investigator-Initiated Studies (IIS) in IBD and to improve the quality of IBD clinical studies in Europe through education. In 2022, awards will be given to the 2 best congress abstracts reporting on clinical studies set up by investigators (preferably multi-centre) submitted for the ECCO Congress. Note: Studies conducted by industry will not be eligible for this award.
Responsible Committee: Clinical Research Committee of ECCO (ClinCom)
Prize: Free registration for the ECCO Congress 2023
Number of awards: 2
Who can apply: ECCO Members reporting on clinical studies set up by investigators in their abstracts. Note: ECCO Membership fee 2022 must be paid up until the abstract submission deadline.
How to apply:
The Young ECCO (Y-ECCO) encourages Y-ECCO Members to submit their abstract and share their research with the ECCO Community. Awards will be given to the 5 best-ranked abstracts along with a free congress registration for the following year.
Responsible Committee: Young-ECCO (Y-ECCO)
Prize: Free registration for the ECCO Congress 2023
Number of awards: 5
Who can apply: Y-ECCO Members (below 35 years of age or still in training). Note: ECCO Membership fee 2022 must be paid up until the abstract submission deadline.
How to apply: